Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized,Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in Primary Open Angle Glaucoma or Ocular Hypertension Patients

NCT03419975 is registered in ClinicalTrials.gov with Taejoon Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03419975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03419975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized,Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in Primary Open Angle Glaucoma or Ocular Hypertension Patients
Lead sponsor
Taejoon Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 26, 2016
Completion date
June 1, 2018
Enrollment
146 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, primary open-angle glaucoma